The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XCUR | -78.02% | -97.68% | -52.88% | -99% |
| S&P | +12.42% | +86.41% | +13.26% | +151% |
Exicure, Inc. develops therapeutics for immuno-oncology, genetic disorders and other indications based on its proprietary Spherical Nucleic Acid. Its product pipeline include Cavrotolimod (AST-008) and XCUR-FXN. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in June 2011 and is headquartered in Skokie, IL.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.07M | 67.8% |
| Gross Margin | 59.80% | 0.0% |
| Market Cap | $25.84M | 330.4% |
| Market Cap / Employee | $3.23M | 0.0% |
| Employees | 8 | 60.0% |
| Net Income | -$2.44M | -123.4% |
| EBITDA | -$2.32M | -89.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.44M | 1193.9% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.03M | -99.5% |
| Short Term Debt | $0.34M | -51.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -71.27% | -37.3% |
| Return On Invested Capital | -130.39% | -9.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3.42M | -662.1% |
| Operating Free Cash Flow | -$3.53M | -685.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 19.22 | 11.87 | 3.91 | 2.92 | -21.67% |
| Price to Sales | 10.41 | 5.54 | 13.18 | 164.77 | - |
| Price to Tangible Book Value | 19.22 | 11.87 | 10.45 | 14.86 | 299.20% |
| Enterprise Value to EBITDA | -61.54 | -24.91 | -15.98 | -9.39 | -6.98% |
| Return on Equity | -197.9% | -86.3% | -150.5% | -217.9% | 64.29% |
| Total Debt | $5.94M | $0.62M | $0.48M | $0.37M | -94.03% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
